{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:03:17Z","timestamp":1783598597248,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.bbmt.2018.08.025","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T14:34:07Z","timestamp":1536849247000},"page":"86-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party"],"prefix":"10.1016","volume":"25","author":[{"given":"Charalampia","family":"Kyriakou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Boumendil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Finel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"NN Norbert Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels Smedegaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Malladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kroschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.08.025_bib0001","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0002","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0003","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","article-title":"Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial","volume":"15","author":"Glass","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0004","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw124","article-title":"Reduced-intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: An analysis from the Lymphoma Working Party of the EBMT [e-pub ahead of print]","author":"Robinson","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0006","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/bmt.2015.348","article-title":"Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas","volume":"51","author":"Heinzelmann","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0007","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0008","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3324\/haematol.2013.084723","article-title":"Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party","volume":"98","author":"Montoto","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0009","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0010","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0011","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2014.223","article-title":"The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Robinson","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0012","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0013","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0014","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2016.04.019","article-title":"Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients","volume":"22","author":"Fenske","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0015","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bbmt.2014.03.013","article-title":"Allotransplantation for patients age \u226540 years with non-Hodgkin lymphoma: encouraging progression-free survival","volume":"20","author":"McClune","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0016","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0017","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2009.21.8073","article-title":"Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia","volume":"28","author":"Lim","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0018","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1001\/jama.2011.1558","article-title":"Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies","volume":"306","author":"Sorror","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0019","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.bbmt.2011.06.005","article-title":"Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission","volume":"17","author":"Farag","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbmt.2016.09.027","article-title":"Allogeneic stem cell transplantation for patients age \u226570 years with myelodysplastic syndrome: a retrospective study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT","volume":"23","author":"Heidenreich","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0021","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/bmt.2016.156","article-title":"Outcome of allogeneic stem cell transplantation for AML and myelodysplastic syndrome in elderly patients (\u226560 years)","volume":"51","author":"Pohlen","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0022","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0023","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1093\/annonc\/mdx556","article-title":"Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial","volume":"28","author":"Glass","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0024","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3109\/10428194.2010.542596","article-title":"Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis","volume":"52","author":"Morgensztern","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0025","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.canep.2011.08.006","article-title":"Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008-2012","volume":"36","author":"Pulte","year":"2012","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0026","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/cncr.30003","article-title":"Changes in the survival of older patients with hematologic malignancies in the early 21st century","volume":"122","author":"Pulte","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0027","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clml.2015.06.005","article-title":"Persistent disparities among patients with T-cell non-Hodgkin lymphomas and B-cell diffuse large cell lymphomas over 40 years: A SEER database review","volume":"15","author":"Crozier","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0028","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0029","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/bmt.2016.20","article-title":"Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually","volume":"51","author":"Passweg","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0030","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1038\/leu.2016.125","article-title":"Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation","volume":"30","author":"Dietrich","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0031","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0032","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0033","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0034","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0035","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0036","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMp1711886","article-title":"Tragedy, perseverance, and chance\u2014the story of CAR-T therapy","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0037","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2017.8","article-title":"Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor","volume":"31","author":"Chen","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0038","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0039","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/stem.2715","article-title":"Concise review: emerging principles from the clinical application of chimeric antigen receptor T cell therapies for B cell malignancies","volume":"36","author":"Jain","year":"2018","journal-title":"Stem Cells"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0040","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood-2013-10-528984","article-title":"Donating used CARs","volume":"122","author":"Rapoport","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0041","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0042","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0043","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2017-08-752121","article-title":"Posttransplant chimeric antigen receptor therapy","volume":"131","author":"Smith","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0044","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.08.025_bib0045","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118305275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118305275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:04:23Z","timestamp":1761059063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118305275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1083879118305275"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.025","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}